EIT Pharma Gains FDA Acceptance for Lonafarnib NDA
Kirkland, Washington, August,11, 2026 EIT Pharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Kirkland, Washington, August,11, 2026 EIT Pharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted...
BASEL, Switzerland, July 14, 2026 Roche has introduced the cobas® Hepatitis D Virus (HDV) test, the first fully automated,...
BOSTON, July 14, 2026 Atea Pharmaceuticals announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, an...
North Chicago, Illinois, USA – May 22, 2026 AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products...
Foster City, California, USA – May 21, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration...
Foster City, California – October 20, 2025 — Gilead Sciences, Inc. (Nasdaq: GILD) announced that it will present new...
